Icosagen AS has incorporated a US subsidiary – Icosagen Technologies, Inc.

In
order to provide better assistance to its US customers, Estonian biotechnology
company Icosagen AS has incorporated a US subsidiary – Icosagen Technologies,
Inc.

This marks a significant
milestone for Icosagen, as well as for the Estonian biotechnology sector in
general. Until now, mainly European companies were able to benefit from
Icosagen’s unique technologies. The decision to make its IP and services more
accessible to US companies has been followed by some customer demand, and it is
expected that the US will become the most important foreign market for
Icosagen. The commitment to the US market will follow the incremental expansion
model, with R&D as well as manufacturing remaining in Estonia during the
first phase. However, as the business grows, they will eventually be moved
closer to the customers.

Icosagen develops
antibodies and manufactures recombinant proteins by using its proprietary
technologies. Icosagen’s patented QMCF technology has been successfully
licensed to a series of large pharmaceutical and biotechnology companies, and
is being used in the development and production of biological therapeutics. The
company is ISO 9001:2008 certified, and follows GLP regulations